Furthermore, DLBCL patients with high CISD2 levels in our cohort (Figures 1C, D, P < 0.05) demonstrated a similar trend in clinical response to the R-CHOP regimen as observed in the GSE117556 dataset. The gene discussed is CISD2; the disease is diffuse large B-cell lymphoma.